| Rheumatoid Arthritis
Naprelan vs Remicade
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Naprelan vs Remicade with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRemicade has a higher rate of injection site reactions vs Naprelan based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Remicade but not Naprelan, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Naprelan
Remicade
At A Glance
Oral
Daily
NSAID
IV infusion
Every 8 weeks
TNF-alpha inhibitor
Indications
- Rheumatoid Arthritis
- Degenerative polyarthritis
- Ankylosing spondylitis
- Tendinitis
- Bursitis
- Gout
- Primary dysmenorrhea
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis, Degenerative polyarthritis, Ankylosing spondylitis 750 mg or 1,000 mg once daily; may be increased to 1,500 mg once daily for limited periods when a higher level of anti-inflammatory/analgesic activity is required.
Tendinitis, Bursitis, Primary dysmenorrhea 1,000 mg once daily; for patients requiring greater analgesic benefit, 1,500 mg may be used for a limited period; total daily dose should not exceed 1,000 mg thereafter.
Gout 1,000-1,500 mg once daily on the first day, followed by 1,000 mg once daily until the attack subsides.
Crohn Disease, Ulcerative Colitis 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks (adults and pediatric patients >= 6 years).
Rheumatoid Arthritis 3 mg/kg IV induction at 0, 2, and 6 weeks, then 3 mg/kg every 8 weeks in combination with methotrexate; dose may be increased up to 10 mg/kg every 8 weeks or every 4 weeks for incomplete responders.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV induction at 0, 2, and 6 weeks, then 5 mg/kg every 8 weeks.
Contraindications
- Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to naproxen or any components of the drug product
- History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab, any inactive ingredient of REMICADE, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
Adverse Reactions
Most common (>=10%) headache, dyspepsia, flu syndrome
Serious cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, hematologic toxicity
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain.
Serious Pneumonia, cellulitis, abscess, sepsis, bacterial infection, hepatotoxicity, acute liver failure, malignancies (including lymphoma), pancytopenia, thrombocytopenia, leukopenia.
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders, anaphylactic shock, cerebrovascular accidents, myocardial ischemia/infarction.
Pharmacology
Naproxen is an NSAID with analgesic, anti-inflammatory, and antipyretic properties that acts by inhibiting cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis in peripheral tissues.
TNF-alpha antagonist; infliximab is a chimeric IgG1 monoclonal antibody that neutralizes the biological activity of TNF-alpha by binding with high affinity to both soluble and transmembrane forms of TNF-alpha and inhibiting its binding to receptors, thereby reducing inflammation in RA, CD, UC, AS, PsA, and Ps.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Naprelan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (10/12)
Remicade
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (0/12)
UnitedHealthcare
Naprelan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Remicade
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Naprelan
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Remicade
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Naprelan.
No savings programs available for Remicade.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NaprelanView full Naprelan profile
RemicadeView full Remicade profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.